Allergan plc / Anterios, Inc.

Hyperhidrosis (primary lead indication; also acne, crow's feet)

$707M Global hyperhidrosis treatment market 2024 (retrospective benchmark)

Disease Overview

Primary hyperhidrosis is excessive, idiopathic sweating that exceeds physiological need, typically affecting axillae, palms, soles, or face. It affects ~4.8% of Americans (~15.3M people) with peak prevalence in 18-39 year olds and meaningful quality-of-life impact. Standard care escalates from topical aluminum chloride to oral anticholinergics, iontophoresis, and injectable BOTOX (FDA approved 2004 for severe primary axillary hyperhidrosis).

Competitive Landscape

When Allergan acquired Anterios in January 2016, the neurotoxin space was dominated by Allergan's own BOTOX (onabotulinumtoxinA, $1.3B in 9M 2015 sales across cosmetic + therapeutic indications), with competition from Galderma's Dysport (abobotulinumtoxinA), Merz's Xeomin (incobotulinumtoxinA), and Revance's then-investigational daxibotulinumtoxinA. All competing products required intramuscular or intradermal injection — limiting penetration in patients fearful of needles, and capping addressable market in dermatology/aesthetic indications like crow's feet and hyperhidrosis. Anterios's NDS (Needle-free Delivery System) platform and ANT-1207 (topical botulinum toxin type A) offered a category-creating non-invasive option. Allergan's strategic logic was to extend the BOTOX franchise across patients deterred by injection — a meaningful hyperhidrosis subsegment given that aluminum chloride first-line topicals cause skin irritation and offer limited durability. Competing topical hyperhidrosis approaches at the time included Dermira's glycopyrronium tosylate wipe (Qbrexza, FDA approved 2018) and various anticholinergic creams. Notably, prior to closing Anterios spun out non-core assets to Eirion Therapeutics, which retained non-exclusive ANT-1207 rights — complicating subsequent development trajectory.